Patient concerns regarding chronic hepatitis B and C infection A.H.M. Alizadeh, 1 M. Ranjbar 2 and M. Yadollahzadeh 1

Similar documents
62 La Revue de Santé de la Méditerranée orientale, Vol. 11, N o 1/2, 2005

Prevalence of smoking among highschool students of Tehran in 2003 G. Heydari, 1 H. Sharifi, 1 M. Hosseini 2 and M.R. Masjedi 1

494 La Revue de Santé de la Méditerranée orientale, Vol. 11, N o 3, 2005

Eastern Mediterranean Health Journal, Vol. 11, No. 3,

590 La Revue de Santé de la Méditerranée orientale, Vol. 14, N o 3, 2008

S118 La Revue de Santé de la Méditerranée orientale, Vol. 12 (Supplément N o 2), 2006

1114 La Revue de Santé de la Méditerranée orientale, Vol. 9, N o 5/6, 2003

Prevent Hepatocellular Carcinoma through Screening, Vaccination, and Treatment of Viral Hepatitis Milena Gould Suarez, MD

your liver Care for Think about hepatitis

Quality of life of patients with schizophrenia 2

Short communication Injuries caused by falls from trees in Tehran, Islamic Republic of Iran M. Zargar, 1 A. Khaji 1 and M.

Hepatitis is an epidemic disease that can be caused by different viruses including hepatitis viruses A, B, C, D or E.

Viral Hepatitis. WHO Regional Office for Europe July 2013

Primary Care Services for blood borne viral hepatitis prevention, treatment and care

Chronic Hepatitis C The Patient s Perspective

Overview of Blood Transfusion System of Iran:

Hepatitis B and human immunodeficiency viruses infection: awareness and universal precautions in Kassala, eastern Sudan

Hepatitis C Cure The Invisible Epidemic

Marc Steben, President Marie-Claude Drouin, Coordinator STBBIs Committee/Unit

Hepatitis Case Investigation

Strategies to Address HCV

Until recently, countries in Eastern

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

Media centre. WHO Hepatitis B. Key facts. 1 of :12 AM.

Global Reporting System for Hepatitis (GRSH) An introduction. WHO Global Hepatitis Programme

Research Article The Association of Hepatitis C Serological Status with Several Risk Factors in Indonesia

Summary of Key Points. WHO Position Paper on Vaccines against Hepatitis B, July 2017

original article Improving access to care by allowing self-referral to a hepatitis C clinic

Need for Chronic Viral Hepatitis Monitoring System

Hepatitis C Best Practice Guidelines For Local Health Departments

Viral Hepatitis B and C in North African Countries

Version for the Silent Procedure 29 April Agenda item January Hepatitis

Epidemiology of Acute Hepatitis C Infection in Canada Results from the Enhanced Hepatitis Strain Surveillance System (EHSSS)

Current Infectious Disease Screening for the Live Organ Donor

Patient Name: MRN: DOB: Treatment Location:

risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV)

Uses and Misuses of Viral Hepatitis Testing. Origins of Liver Science

Rates of depression and anxiety among female medical students in Pakistan F. Rab, 1 R. Mamdou 2 and S. Nasir 1

School Nursing and Health. Standard Precautions. (aka Universal Precautions)

Practical Solutions to Reduce Incidence of Liver Cancer. Nancy Steinfurth, Executive Director Liver Health Connection November 2017

Digestive & Liver Disease Wellness

Adepoju,V.A 1, Ekerete-Udofia,C, 2 Okafor,V 3, Ogbudebe,C 4

New Brunswick Report on Sexually Transmitted and Blood Borne Infections, 2016

CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE

Epidemiology of Hepatitis C Iran

Improving Access & Linkage to Care in Underserved Populations & Baby Boomers

Assessing and Enhancing HIV Vaccine Trial (HVT) Consent Preparedness Among Street Drug Users

HIV Prevention, Hepatitis Programming, and Drug User Health An Integrated Service Model at SFDPH. Protecting and Promoting Health and Equity

VIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES IN THE AFRICAN REGION. Report of the Secretariat. CONTENTS Paragraphs BACKGROUND...

Confirmed (Laboratory Tests) Serum positive for IgM anti-hbc or, hepatitis B surface antigen (HbsAg).

VIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES IN THE AFRICAN REGION. Report of the Secretariat. CONTENTS Paragraphs BACKGROUND...

Hepatitis C infection affects over 170 million people worldwide,

Hepatitis C COLVILLE FOCUSED DIAGNOSIS, MANAGEMENT, TREATMENT

Taken From VBA s Adjudication Procedure Manual Section on Hepatitis

Patients with chronic hepatitis C Who should not be treated?

Hepatitis STARS Program. Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003

Eastern Mediterranean Health Journal, Vol. 14, No. 1,

UGANDA POPULATION-BASED HIV IMPACT ASSESSMENT UPHIA

Profile of cancer family clustering in Jordan S.A. Khoury 1 and D.F. Mas ad 2

Original article J Bas Res Med Sci 2017; 4(2):4-8.

EAST LONDON INTEGRATED CARE

Increase Hepatitis B Screening and Vaccinations

Module 1: HIV epidemiology, transmission and prevention

ORIGINAL ARTICLE Indications for interferon/ribavirin therapy in hepatitis C patients: Findings from a survey of Canadian hepatologists

620 La Revue de Santé de la Méditerranée orientale, Vol. 10, N o 4/5, 2004

High Yield and Feasibility of Baby Boomer Birth Cohort HCV Screening in Two Urban, Academic Emergency Departments

Hepatitis C and Innovative Public Health Practice

Primary and acquired drug resistance in childhood tuberculosis S. Khalilzadeh, 1 M.R. Boloorsaz, 1 A. Safavi, 1 P. Farnia 1 and A.A.

Seroprevalence of HAV among Male patients living with HBV at four private hospitals in Southwestern Nigeria

The Hepatitis B-e antigen-positive

Hepatitis C in Massachusetts Michael Gaucher and Shauna Onofrey MA Department of Public Health Bureau of Infectious Disease & Laboratory Sciences

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

Commonly Asked Questions About Chronic Hepatitis C

HIV in the UK: Changes and Challenges; Actions and Answers The People Living With HIV Stigma Survey UK 2015 Scotland STIGMA SURVEY UK 2015

in pregnancy Document Review History Version Review Date Reviewed By Approved By

Prevalence of hepatitis G virus in liver disease

1338 La Revue de Santé de la Méditerranée orientale, Vol. 14, N o 6, 2008

Pattern and outcome of diabetic admissions at a federal medical center: A 5-year review

Epidemiology and Screening for Hepatitis C Infection

Section 3: Testing and Diagnosis of Hepatitis C

ABOUT HEPATITIS C DIAGNOSED IN THE HOSPITAL STAFF OF CHU TLEMCEN

Does the Addition of HCV Testing to a Rapid HIV Testing Program Impact HIV Test Acceptance? A Randomized Controlled Trial.

Jackie Williams BBV/Sexual Health Trainer

26/09/2014. Types of Viral Hepatitis. Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges

Is Elimination of Hepatitis C Possible?

JMSCR Vol 3 Issue 10 Page October 2015

Hepatitis B infection

HIV Testing. ECHO Hep C. Judith Feinberg, MD June 22, 2017

Bloodborne Pathogens and Universal Precautions

SEROPREVALENCE OF ANTI-HCV ANTIBODIES AMONG VOLUNTARY BLOOD DONORS IN FATEHABAD DISTRICT OF HARYANA

Edinburgh Access Practice Hepatitis C Clinic Jessie Anderson, Kim McBeth, John Budd and Rebecca Martin

Hepatitis B Vaccination and Prevention. Angela M. Jo, MD, MSHS

Personal Details: First Name: Shahnaz Surname: Sali Date of Birth: 6 th September 1968 Place of Birth: Arak. Marital Status: Married, one son

Hepatitis C (Hep C) By Joshua Rollins. Transmission/Reservoirs

Hepatitis C Policy Discussion

Eliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific

Viral Hepatitis. Background

iphis Case ID #: Reported Date: Reporting Source: Diagnosing Health Unit: Branch Office: Outbreak Number:

The Geography of Viral Hepatitis C in Texas,

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University

Transcription:

1142 La Revue de Santé de la Méditerranée orientale, Vol. 14, N o 5, 2008 Patient concerns regarding chronic hepatitis B and C infection A.H.M. Alizadeh, 1 M. Ranjbar 2 and M. Yadollahzadeh 1 80.6 44.4 50.0 66.7 33.3 36.1 36.1 41.7 5.6 5.6 22.2 25 ABSTRACT Counselling of patients with viral hepatitis is often limited to discussions about how the virus is transmitted. The aim of the present study was to document the principal concerns of patients suffering from chronic hepatitis B and C infection. The most common volunteered concerns were infecting family members (80.6%), infecting others (66.7%), side-effects of treatment (50.0%), disease progression to cirrhosis (44.4%), loss of employment (41.7%), liver transplantation (36.1%), social stigma (36.1%), change in lifestyle (33.3%), development of liver cancer (25%), costs and money (22.2%), fear of disease (5.6%) and psychological disease (5.6%). Health care providers who focus counselling efforts exclusively on viral transmission are unlikely to address other important concerns. Préoccupations des patients concernant les hépatites chroniques B et C RÉSUMÉ Le conseil aux patients atteints d hépatite virale se limite souvent à des discussions sur le mode de transmission du virus. L objectif de la présente étude était de recueillir des informations sur les principales préoccupations des patients atteints d hépatite chronique B ou C. Les préoccupations les plus souvent citées spontanément étaient la crainte d infecter les membres de la famille (80,6 %), la crainte d infecter les autres (66,7 %), les effets secondaires du traitement (50,0 %), l évolution de la maladie vers la cirrhose (44,4 %), la perte d emploi (41,7 %), une greffe du foie (36,1 %), les préjugés (36,1 %), le changement de mode de vie (33,3 %), le développement d un cancer du foie (25 %), les coûts et les questions d argent (22,2 %), la peur de la maladie (5,6 %) et les maladies psychologiques (5,6 %). Les prestataires de soins de santé qui ne s intéressent qu à la transmission du virus dans le cadre de leurs activités de conseil risquent de ne pas répondre aux autres préoccupations importantes des patients. 1 Research Centre for Gastroenterology and Liver Disease, Shaheed Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran (Correspondence to A.H.M. Alizadeh: ahmaliver@yahoo.com). 2 Department of Infectious Disease, Iran University of Medical Sciences, Tehran, Islamic Republic of Iran. Received: 29/01/06; accepted: 12/06/06

Eastern Mediterranean Health Journal, Vol. 14, No. 5, 2008 1143 Introduction The estimated global prevalence of viral hepatitis is around 3% 5%, which means that approximately 400 million people are infected with hepatitis B virus (HBV) [1] and around 170 million with hepatitis C virus (HCV) [1 4]. Given the variability that exists with respect to the features and outcome of chronic HBV and HCV infection, appropriate counselling to address patient concerns is an integral component of patient management. Yet the precise content of that counselling remains to be defined. In those few reports that specifically address counselling in HCV-infected individuals, the focus has largely been on routes of viral transmission and what can be done to decrease the risk of transmission to others [5 8]. To date, only one study has prospectively documented the principal concerns of infected individuals [2] and what should be incorporated into patient counselling. The present study aimed to document the principal concerns about HBV and HCV infection of patients attending a viral hepatitis clinic in Tehran, Islamic Republic of Iran, to provide information for future counselling strategies. Methods This descriptive study was conducted during April to September 2005 on consecutive patients with hepatitis B or C who were admitted to a viral hepatitis clinic in Tehran, Islamic Republic of Iran. The referral clinic is staffed by gastroenterologists and serves patients with hepatitis. The diagnosis of hepatitis was based on history of HBV surface antigen (HBsAg) or HCV antibody (HCVAb) positivity in 2 separate laboratory examinations. Patients with other documented transmittable diseases such as HIV, mentally retarded patients and those less than 14 years old were excluded. A physician or nurse interviewed each patient in private. No patient refused to be interviewed. Patients were initially asked in an open-ended manner about their principal concern regarding their HBV or HCV infection (volunteered concern). In most patients more than 1 principal concern was volunteered. Patients were then provided with a list of 8 potential concerns and asked to prioritize them. The list had been developed by the attending physicians and the priority scores ranged from 1 (most important) to 8 (least important). The following items were included in the list of concerns: social stigma of having liver disease; loss of employment; development of liver cancer; development of cirrhosis; infecting family members; infecting others; requiring a liver transplant; and side-effects of treatment. The categorization process was performed in a semi-blinded fashion such that physicians were unaware of the nature of the patient (HBV or HCV infected) or their demographic status. We also documented whether these concerns varied with respect to the demographic characteristics of the patient population, including age, sex, ethnicity, level of education, marital status, employment (yes or no), mode of acquisition of the virus, residence (urban/rural) and type of hepatitis (HBV or HCV). All data were analysed with SPSS, version 13. Continuous variables were summarized as mean and standard deviation (SD), and frequencies were shown by percentages. Results The demographic characteristics of the 36 patients interviewed during the 6-month

1144 La Revue de Santé de la Méditerranée orientale, Vol. 14, N o 5, 2008 study period (19 with chronic HBV infection and 12 with chronic HCV) are shown in Table 1. The mean (SD) age of patients was 32.1 (11.2) years. The mean follow-up Table 1 Demographic characteristic of the study patients with chronic hepatitis B virus (HBV) or C virus (HCV) infection Characteristic Overall Hepatitis C Hepatitis B P-value a (n = 36) cases cases (n = 12) (n = 19) No. % No. % No. % Age Mean (SD) (years) 32.1 (11.2) 32.9 (10.0) 32.8 (13.2) 0.97 Sex 0.108 Male 28 77.8 11 91.7 12 63.2 Female 8 22.2 1 8.3 7 36.8 Ethnicity 0.026 Turk 6 16.7 0 0.0 4 21.1 Kurd 9 25.0 1 8.3 7 36.8 Fars 20 55.6 11 91.7 7 36.8 Lurs 1 2.8 0 0.0 1 5.3 Education 0.783 Below grade 12 15 41.7 5 41.7 7 36.8 High-school diploma 11 30.6 4 33.3 5 26.3 University 10 27.8 3 25.0 7 36.8 Marital status 0.710 Single 14 38.9 6 50.0 7 36.8 Married 22 61.1 6 50.0 12 63.2 Employment 1.000 No 18 51.4 5 45.5 9 47.4 Yes 17 48.6 6 54.5 10 52.6 Mode of acquisition of virus 0.014 Unknown 15 41.7 3 25.0 8 42.1 Injection 4 11.1 4 33.3 0 0.0 Sexual contact 2 5.6 0 0.0 2 10.5 Transfusion 4 11.1 2 16.7 2 10.5 Congenital 3 8.3 0 0.0 3 15.8 Dentistry 4 11.1 0 0.0 4 21.1 Needlestick 2 5.6 1 8.3 0 0.0 Tattoo 2 5.6 2 16.7 0 0.0 Residence 1.000 Urban 27 77.1 9 75.0 14 77.8 Rural 8 22.9 3 25.0 4 22.2 Follow-up Mean duration (SD) (months) 21.9 (25.2) 7.6 (7.5) 33.1 (29.3) 0.005 a P-values are based on 2-tailed Fisher exact, Yates corrected χ 2 test or independent samples t-test, as appropriate, between patients with HBV and HCV infection (P < 0.05 is significant). SD = standard deviation.

Eastern Mediterranean Health Journal, Vol. 14, No. 5, 2008 1145 period was 21.9 (25.4) months; 77.8% of cases were followed up for 24 months (range 0 108 months). The majority were male (28 cases; 77.8%) and living in the city (27 cases; 77.1%). There was a relatively even distribution of education level attained, marital status, employment, ethnicity and (volunteered) mode of acquisition of the virus. The principal concerns that were volunteered spontaneously by patients are shown in Table 2. The most common concern was infecting family members (80.6%), followed by infecting others (66.7%) and side-effects of treatment (50.0%). When the results were analysed by mean score, the rankings for volunteered concerns were slightly different; the highest priority [mean score (SD)] was for infecting family members [1.76 (SD 1.18], followed by fear of disease [2.50 (SD 2.12)], disease progression to cirrhosis [2.69 (SD 1.53)] and infecting others [2.83 (SD 1.34)] (Table 2). From the list of potential concerns presented to patients the highest priority [mean score (SD)] was given to infecting family members [2.59 (SD 1.98)], followed by disease progression to cirrhosis [2.87 (SD 1.58)], infecting others [3.71 (SD 1.88)] and developing liver cancer [4.03 (SD 2.11)] (Table 2). The most common concerns were analysed by demographic characteristic. Infecting family members was the most common volunteered concern of HBV patients among males (66.7%), Fars ethnicity (71.4%), below grade 12 education (57.1%), highschool diploma education (80%), single (57.1%), married (66.7%), unemployed (55.6%), employed (70.0%) and living in a village (100%). However, side-effects of treatment was the most common vol- Table 2 Distribution and ranking of principal concerns (both volunteered and those presented as a list) of patients with chronic hepatitis B or C infection (n = 36) Concern Volunteered List presented by patients to patients % a Mean (SD) Mean (SD) score b score b Fear of disease 5.6 2.50 (2.12) Costs and money 22.2 3.63 (2.72) Lifestyle change 33.3 4.83 (2.82) Psychological disease 5.6 7.00 (2.82) Infecting family 80.6 1.76 (1.18) 2.58 (SD 1.98) Disease progression (cirrhosis) 44.4 2.69 (1.53) 2.87 (SD 1.58) Infecting others 66.7 2.83 (1.34) 3.70 (SD 1.88) Developing liver cancer 25.0 4.00 (2.06) 4.03 (SD 2.11) Side-effects of treatment 50.0 3.83 (1.75) 4.93 (SD 1.84) Need for liver transplant 36.1 4.69 (1.60) 5.20 (SD 1.49) Social stigma 36.1 4.15 (2.60) 5.35 (SD 2.54) Loss of employment 41.7 4.60 (2.72) 6.00 (SD 2.35) a % of patients mentioning this concern. b Lower score = higher ranking. SD = standard deviation.

1146 La Revue de Santé de la Méditerranée orientale, Vol. 14, N o 5, 2008 unteered concern of patients with HBV infection among females (71.4%), university education (71.4%), congenital mode of acquisition (100%) and urban residence (64.3%). Infecting others was the most common concern among Turks (100%) and loss of employment among Kurds (57.1%). On the other hand, the commonest volunteered concern in all subgroups of patients with HCV infection was infecting family members. Discussion The results of this study indicate the most common concern in patients with chronic HBV and HCV infection relate to viral transmission. The other concerns were disease progression, side-effects of treatment and loss of employment. Similar results were obtained in both subgroups of HBV- and HCV-infected patients. With a few exceptions, these concerns were consistent regardless of sex, ethnicity, level of education, marital status, employment, mode of viral acquisition and residence of patients. Differences between rank order of the volunteered concerns in HBV- and HCV-infected patients may be influenced by follow-up duration, mode of acquisition or ethnicity, but the 3 first concerns in both groups of patients were the same. As discussed earlier, the principal focus of patient counselling for HCV-infected individuals described in previous reports is what can be done to decrease the risk of viral transmission to others [5 7,9]. According to the results of this study, the risk of viral transmission to family members and others, when combined, represented the volunteered concern of 66.7% to 80.6% of patients. Thus, if counselling were limited to discussions about HBV and HCV transmission, the main concerns of approximately 60% 80% of infected individuals would be addressed. Of course, we should consider that the high concern about transmitting the infection to others may have resulted from the participants desire to please the interviewer and give a response that seemed most appropriate and least selfish. Disease progression is a general term that describes patients concern that the disease would get worse or I will become too tired in the future to do what I can do now. It was considered a distinct concern if patients failed to offer a specific outcome such as cirrhosis or liver cancer from that progression. If considered as one principal concern, based on the results of both volunteered and prioritized rankings, cirrhosis was the most feared outcome of disease progression, followed by liver cancer and liver transplantation. In practical terms, the relative consistency of findings across the various demographic profiles of patients facilitates counselling efforts in HBV- or HCV-infected individuals [7]. For example, regardless of whether patients are employed or unemployed, male or female, HBV-infected or HCV-infected, etc., if physicians address the issues of disease progression, side-effects of treatment and infection of family members or others, the principal concerns of these patients will have been addressed. The limitations of this study include the following: first, investigators could not control the extent of counselling provided to newly diagnosed patients by their referring physicians in the community. However, based on the differences between volunteered and prioritized concerns, it would appear that such counselling was limited. Secondly, although the centre to which the patients were referred tends to see the majority of HBV- and HCV-diagnosed cases in the region, we cannot rule out referral bias. Thirdly, because of the cross-sectional design of the study, patients were not fol-

Eastern Mediterranean Health Journal, Vol. 14, No. 5, 2008 1147 lowed to determine whether their concerns changed with time. Finally, similar data do not exist in the medical literature. Hence, we cannot determine whether these findings are site-specific. In summary, counselling of HBV- and HCV-infected patients that is limited to discussions about viral transmission would satisfy the principal concerns of approximately 60% 80% of patients. But disease progression and side-effects of treatment and loss of employment are also common concerns of patients with chronic HBV and HCV. 1. Szabó E et al. Viral hepatitis: new data on hepatitis C infection. Pathology and oncology research, 2003, 9(4):215 21. 2. Minuk GY et al. Patient concerns regarding chronic hepatitis C infections. Journal of viral hepatitis, 2005, 12(1):51 7. 3. Lauer GM, Walker BD. Hepatitis C virus infection. New England journal of medicine, 2001, 345:41 52. 4. Davis GL et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. New England journal of medicine, 1989, 321:1501 6. 5. Chan SE, Rosen HR. Outcome and management of hepatitis C in liver transplant References recipients. Clinical infectious diseases, 2003, 37:807 12. 6. Becherer PR, Bacon B. Hepatitis C testing: interpretation, implications and counseling. Missouri medicine, 1993, 90:31 5. 7. Zarski JP, Leroy V. Counselling patients with hepatitis C. Journal of hepatology, 1999, 31:136 40. 8. Zweben JE. Hepatitis C: education and counseling issues. Journal of addictive diseases, 2001, 20:33 42. 9. Feray C et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology, 1999, 117:619 25.